Product Pathways - Growth Factors/Cytokines
Human Interleukin-21 (hIL-21) #8920
|8920LC||50 µg (With Carrier)||---||In Stock||---|
|8920LF||50 µg (Carrier Free)||---||In Stock||---|
|8920SC||10 µg (With Carrier)||---||In Stock||---|
|8920SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human IL-21 (hIL-21) Gln30-Ser155 (Accession # NM_021803) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant hIL-21 contains no "tags" and the nonglycosylated protein has a calculated MW of 15,463. DTT-reduced and non-reduced protein migrate as 16 kDa polypeptides, with non-reduced having slightly greater mobility due to intramolecular cystines. The expected amino-terminal QGQDR of recombinant hIL-21 was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-21. Less than 9% is nicked after Arg114 to generate 6 kDa and 10 kDa polypeptides observed in reduced (+) hIL-21.
The bioactivity of recombinant hIL-21 was determined by its ability to induce IFN-γ production by NK-92 cells. The ED50 of each lot is between 1.0-6.0 ng/ml.
The purity of recombinant hIL-21 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIL-21 and staining overnight with Coomassie Blue.
The production of IFN-γ by NK-92 cells cultured with increasing concentrations of hIL-21 was assessed. Media from cells incubated with hIL-21 for 24 hours was collected and assayed for IFN-γ by ELISA and the OD450 was determined.
Western blot analysis of extracts from NK-92 cells, untreated or treated with hIL-21 for 15 minutes, using Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145 (upper) or Stat3 Antibody #9132 (lower).
Less than 0.01 ng endotoxin/1 μg hIL-21.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-21. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
IL-21 is produced by Th17, T follicular helper (Tfh) and NKT cells (1-3). Targets include T cells, B cells, NK cells and dendritic cells (1-3,5). IL-21 induces proliferation and activation of NK cells, thereby up-regulating IFN-γ production and cytotoxic activity (1,3,4). IL-21 increases proliferation and survival of CD40 primed B cells (1,2) and appears to have a significant role in plasma cell differentiation (2). IL-21 binds to a complex consisting of IL-21Rα and the common γ chain, γc. IL-21 binding activates the Jak1/Jak3, Stat1, Stat3 and Stat5 pathway. IL-21 binding can also activate the MAP kinase and PI3K/Akt pathways.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.